



Published on *Meeting Library* (<http://meetinglibrary.asco.org>)

[Home](#) > 115550-132

The role of prognostic factors in metastatic renal cell carcinoma (mRCC) treated with targeted therapies (TT): Data from an Italian retrospective multicentric study.

Meeting:

2013 ASCO Annual Meeting

Category:

Genitourinary (Nonprostate) Cancer

Subcategory:

Kidney Cancer

Session Type and Session Title:

This abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting.

Abstract Number:

e15512

Citation:

J Clin Oncol 31, 2013 (suppl; abstr e15512)

Author(s):

Carmen Barile, Anna Paola Fracon, Fable Zustovich, Fernando Gaion, Luigi Salvagno, Francesco Massari, Ignazio Martellucci, Caterina Modenesi, Mauro Giusto, Romana Segati, Alessandra Bearz, Chiara Ogliosi, Sveva Macrini, Marco Maruzzo, Francesca Larussa, Linda Nicolardi, Giorgio Bonciarelli, Daniela Menon, Alessandro Inno, Felice Pasini; Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy; Casa di Cura Pederzoli, Peschiera del Garda, Italy; Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padova, Italy; Department of Medical Oncology, U.L.S.S. 15, Camposampiero, Italy; Ospedale di Vittorio Veneto, Vittorio Veneto, Italy; Oncologia, Verona, Italy; Oncologia Medica, Siena, Italy; Oncologia Medica, Este, Italy; Oncologia Medica Ospedale, Belluno, Italy; Oncologia Ospedale, Feltre, Italy; IRCCS Centro Rif Oncologico, Pordenone, Italy; Oncologia Medica Fondazione Poliambulanza, Brescia, Italy; University Hospital, Udine, Italy; Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy; Azienda Ospedaliera Universitaria Integrata, Verona, Italy; ULSS 4, Thiene, Italy; Azienda ULSS 18 Rovigo, Rovigo, Italy

Background: Several prognostic factors in mRCC have been largely described in the literature. This study was aimed to verify whether some of these factors maintain their prognostic role in a cohort of pts treated in the community setting outside clinical trials. **Methods:** 902 pts with mRCC treated with TT from 2007 to December 2012 in 28 Italian centres were included in the analysis. Various potential prognostic factors were correlated with overall survival (OS). **Results:** Median age was 60 (range 25-89), 75% of pts were males; median OS (mOS) was 24 mo. Histology was clear cell (CC), CC with sarcomatoid component, papillary, NOS, not available in 82%, 6%, 4%, 4% and 4 %, respectively. mOS in the CC subgroup was 28 vs 12.5 mo of the non CC subset (p<0.001). Nephrectomy was performed in 88% of the cases. mOS of these pts was 28 mo vs 6.5 in those without surgery (p<0.001). The number of metastatic sites was >2 in 43% of

the pts. mOS of this group was 18 mo vs 31 mo of pts with ≤ 2 metastatic sites ($p=0.0001$). MSKCC risk was good in 32%, intermediate in 53% and poor in 15% of the pts. According to MSKCC risk score, mOS was 6.4, 24 and 49 mo in poor, intermediate and good subsets, respectively ($p<0.001$). The small subset of pts (2%) with both thrombophilia and neutrophilia had a dismal mOS of 3 mo. PS (ECOG) was 0-1 in 90% of the pts; mOS of pts with PS ≥ 2 was 6 mo ($p=0.0001$). The findings of multivariate analysis are showed in the Table. **Conclusions:** The results of our survey confirm that clear cell histology, prior nephrectomy, number of metastatic sites, PS, MSKCC risk, platelets, and neutrophils count maintain their prognostic value also in mRCC pts treated with TT in the everyday clinical practice.

	HR (95%CI)	P
Sex		
Males vs females	0,94 (0,7-1,24)	NS
Age		
≤ 60 vs >60	0,88 (0,69-1,13)	NS
Histology		
CC vs non CC	0,52 (0,38-0,70)	$<0,001$
Prior nephrectomy		
Yes vs no	0,46 (0,31-0,68)	$<0,001$
Metastatic sites		
≤ 2 vs >2	0,69 (0,53-0,89)	0,004
PS (ECOG)		
0-1 vs >1	0,23 (0,16-0,33)	$<0,001$
MSKCC risk		
Good vs intermediate/poor	0,52 (0,38-0,70)	$<0,001$
Platelets count		
Normal/low vs high	0,52 (0,34-0,80)	0,003
Neutrophils count		
Normal/low vs high	0,43 (0,30-0,63)	$<0,001$

Source URL: <http://meetinglibrary.asco.org/content/115550-132>